News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
487,186 Results
Type
Article (8017)
Company Profile (141)
Press Release (479028)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166739)
Career Advice (304)
Deals (25738)
Drug Delivery (7)
Drug Development (52873)
Employer Resources (14)
FDA (9760)
Job Trends (8572)
News (238192)
Policy (17898)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (494)
Accelerated approval (27)
ADA (18)
Adcomms (1)
Allergies (100)
Alliances (33157)
ALS (115)
Alzheimer's disease (991)
Antibody-drug conjugate (ADC) (304)
Approvals (10444)
Artificial intelligence (349)
ASCO (160)
Autoimmune disease (232)
Automation (32)
Bankruptcy (263)
Belgium (3)
Best Places to Work (6957)
BIO (36)
Biologics (23)
BIOSECURE Act (1)
Biosimilars (122)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (7)
Bladder cancer (140)
Brain cancer (34)
Breast cancer (527)
Cancer (3879)
Cardiovascular disease (234)
Career advice (245)
Career pathing (1)
CAR-T (184)
CDC (1)
CDMO (25)
Celiac Disease (3)
Cell therapy (502)
Cervical cancer (36)
Clinical research (48277)
Collaboration (1329)
Commercialization (17)
Compensation (1595)
Complete response letters (35)
COVID-19 (764)
CRISPR (66)
C-suite (836)
Cystic fibrosis (88)
Data (6144)
Denatured (4)
Depression (108)
Dermatology (90)
Diabetes (375)
Diagnostics (4239)
Digital health (40)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (167)
Drug pricing (7)
Drug shortages (3)
Duchenne muscular dystrophy (172)
Earnings (73809)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88440)
Executive appointments (726)
Eye disease (3)
FDA (12604)
Fibrodysplasia Ossificans Progressiva (11)
Fragile X (1)
Friedreich's ataxia (19)
Frontotemporal dementia (25)
Funding (985)
Gene editing (129)
Generative AI (11)
Gene therapy (343)
GLP-1 (303)
Government (948)
Grass and pollen (2)
Guidances (281)
Healthcare (9375)
Hematology (94)
HIV (55)
Huntington's disease (24)
Idiopathic pulmonary fibrosis (5)
IgA nephropathy (72)
Immunology and inflammation (111)
Immuno-oncology (64)
Indications (172)
Infectious disease (962)
Inflammatory bowel disease (135)
Inflation Reduction Act (4)
Influenza (87)
Intellectual property (269)
Interviews (41)
IPO (12392)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (17)
Kidney disease (62)
Layoffs (59)
Legal (5195)
Licensing (33)
Liver cancer (46)
Longevity (21)
Lung cancer (560)
Lung diease (8)
Lymphoma (263)
Machine learning (29)
Management (3)
Manufacturing (601)
Marketing (12)
MASH (120)
Medical affairs (2)
Medical device (8702)
Medtech (8874)
Mergers & acquisitions (14437)
Metabolic disorders (753)
mRNA (70)
Multiple sclerosis (110)
Multispecific (1)
NASH (4)
Netherlands (1)
Neurodegenerative disease (235)
Neuropsychiatric disorders (40)
Neuroscience (1912)
Neurotech (1)
NextGen: Class of 2026 (3150)
Non-profit (843)
Obesity (235)
Opinion (10)
Ovarian cancer (174)
Pain (183)
Pancreatic cancer (220)
Parkinson's disease (214)
Partnered (12)
Patents (520)
Patient advocacy (2)
Patient recruitment (541)
Patient selection (28)
Peanut (33)
People (41455)
Peptides (11)
Pharmaceutical (30)
Pharmacy benefit managers (10)
Phase 1 (15580)
Phase 2 (21564)
Phase 3 (14554)
Pipeline (8123)
Policy (18)
Postmarket research (1570)
Preclinical (6574)
Press Release (34)
Prostate cancer (199)
Psychedelics (10)
Radiopharmaceuticals (201)
Rare diseases (614)
Real estate (3024)
Recruiting (6)
Regenerative medicine (10)
Regulatory (15107)
Reports (23)
Research institute (589)
Resumes & cover letters (45)
Rett syndrome (45)
RNA editing (8)
RSV (49)
Schizophrenia (108)
Series A (172)
Series B (125)
Service/supplier (5)
Sickle cell disease (64)
Spinal muscular atrophy (92)
Sponsored (5)
Startups (2021)
Stem cells (1)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (53)
Vaccines (342)
Venture capital (17)
Weight loss (76)
Wet AMD (1)
Women's health (94)
Date
Today (67)
Last 7 days (348)
Last 30 days (1475)
Last 365 days (19200)
2026 (14821)
2025 (19252)
2024 (22987)
2023 (26538)
2022 (34586)
2021 (37167)
2020 (33468)
2019 (23257)
2018 (17469)
2017 (18765)
2016 (17917)
2015 (24263)
2014 (21679)
2013 (18135)
2012 (20221)
2011 (20440)
2010 (20332)
Location
Africa (230)
Alabama (80)
Alaska (2)
Arizona (315)
Arkansas (12)
Asia (18010)
Australia (2114)
California (12668)
Canada (3321)
China (562)
Colorado (516)
Connecticut (441)
Delaware (219)
Europe (24752)
Florida (1909)
Georgia (400)
Hawaii (3)
Idaho (46)
Illinois (752)
India (57)
Indiana (330)
Iowa (17)
Japan (443)
Kansas (104)
Kentucky (33)
Louisiana (27)
Maine (27)
Maryland (1255)
Massachusetts (8292)
Michigan (319)
Minnesota (587)
Mississippi (4)
Missouri (83)
Montana (20)
Nebraska (11)
Nevada (128)
New Hampshire (60)
New Jersey (2784)
New Mexico (12)
New York (2976)
North Carolina (1344)
North Dakota (4)
Northern California (6398)
Ohio (301)
Oklahoma (14)
Oregon (16)
Pennsylvania (2358)
Puerto Rico (24)
Rhode Island (30)
South America (407)
South Carolina (79)
South Dakota (1)
Southern California (5276)
Tennessee (128)
Texas (2088)
United States (41074)
Utah (384)
Vermont (1)
Virginia (162)
Washington D.C. (39)
Washington State (975)
West Virginia (1)
Wisconsin (81)
Wyoming (1)
487,186 Results for "epicypher inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
EpiCypher and New England Biolabs Expand Strategic Partnership to Advance Epigenomics Research
May 19, 2026
·
4 min read
Press Releases
PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow
September 4, 2025
·
4 min read
EpiCypher® announces automated CUT&RUN platform for high-throughput epigenomics
EpiCypher announces the development of a fully automated CUT&RUN assay (autoCUT&RUN) for high-throughput mapping of chromatin features. Based on EpiCypher’s industry-leading CUTANA® CUT&RUN kits
November 20, 2023
·
3 min read
Bio NC
AtlasXomics and EpiCypher announce partnership to commercialize spatial epigenomics assays
AtlasXomics and EpiCypher announce their partnership to develop CUT&Tag kits and assay services for spatial epigenomics applications.
January 23, 2024
·
4 min read
Press Releases
EpiCypher Expands Exclusive Licensing Agreement to Advance CUT&Tag Technology
September 4, 2024
·
3 min read
Press Releases
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
October 1, 2026
·
2 min read
Press Releases
Mint Pharmaceuticals Inc. and Bayer Inc. Expand Distribution Partnership in Canada
October 6, 2026
·
3 min read
Business
EpiCypher® signs agreement with Thermo FIsher Scientific to deliver best-in-class ChIP-grade antibodies specific for histone PTMs
EpiCypher® announced the signing of an agreement with Thermo Fisher Scientific, the world leader in servicing science, to provide co-exclusive use of EpiCypher’s SNAP-ChIP® technology.
April 24, 2019
·
1 min read
Bio NC
EpiCypher SNAP-ChIP® technology poised to transform market for histone PTM antibodies
A recently published report in Molecular Cell validates the use of EpiCypher’s proprietary SNAP-ChIP® technology for profiling antibody specificity and sensitivity.
October 9, 2018
·
1 min read
Bio NC
EpiCypher® announces the launch of CUTANA™ (ChIC / CUT&RUN / CUT&Tag) for next-generation genomic mapping studies
EpiCypher, Inc. announces the commercial licensing of ChIC (University of Geneva) and CUT&RUN / CUT&Tag (Fred Hutchinson Cancer Research Center) technologies.
July 23, 2019
·
3 min read
1 of 48,719
Next
